Lake Street initiated coverage of OrthoPediatrics (KIDS) with a Buy rating and $37 price target OrthoPediatrics has proven out its founding thesis that a focused pediatric orthopedics firm is needed and can generate strong economic returns, says the analyst, who argues that the company “occupies a Goldilocks position in an overlooked market.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics: Strong Market Position and Growth Potential Justify Buy Rating with $50 Price Target
- Orthopediatrics Corp Faces Financial Uncertainty Amidst Trade and Regulatory Challenges
- OrthoPediatrics Corp’s Earnings Call Highlights Growth and Record Impact
- OrthoPediatrics price target lowered to $32 from $40 at Stifel
- OrthoPediatrics’ Promising Growth Prospects Reinforce Buy Rating